Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. - Wikidata - awgldk - TriplyDB

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

http://www.wikidata.org/entity/Q51555214

about

Homocysteine in Renal Injury Metabolic syndrome and kidney disease: a systematic review and meta-analysis Management of diabetic nephropathy Identifying and slowing progressive chronic renal failure Perfluoroalkyl chemicals and chronic kidney disease in US adults Statins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis Risk Urine creatinine in treatment-naïve HIV subjects in eastern Nigeria Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study.End-stage renal disease in young black males in a black-white population: longitudinal analysis of the Bogalusa Heart Study.Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15).High prevalence of chronic kidney disease in Iran: a large population-based study.Metabolic syndrome and chronic kidney disease in an adult Korean population: results from the Korean National Health Screening.Arterial stiffness and renal impairment in non-proteinuric type 2 diabetic patients.Disorders of lipid metabolism and chronic kidney disease in the elderly Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy.A simple algorithm to predict incident kidney disease.Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials.Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study.Serum lipid profiles, lipid ratios and Chronic Kidney Disease in a Chinese population Risk factors for progression of chronic kidney disease.Relationship between chronic kidney disease and metabolic syndrome: current perspectives Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.Calcium supplementation increases blood creatinine concentration in a randomized controlled trial.Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice Recent developments in HIV-related kidney disease.Association of dyslipidemia with renal outcomes in chronic kidney disease.Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.Metabolic syndrome and renal injury Endogenous female sex hormones delay the development of renal dysfunction in apolipoprotein E-deficient mice Dynamic changes of early-stage aortic lipid deposition in chronic renal failure rats and effects of decorin gene therapy.Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus Body mass index and metabolic factors predict glomerular filtration rate and albuminuria over 20 years in a high-risk population Glomerulopathy in spontaneously obese rhesus monkeys with type 2 diabetes: a stereological study.Elevated Blood Pressure and Serum γ -Glutamyltransferase as Significant Characteristics of Smokers With Chronic Kidney Disease.Orthostatic hypotension and incident chronic kidney disease: the atherosclerosis risk in communities study.Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study Lipid levels and renal function decline in pre-dialysis patients.Non-dipper status and left ventricular hypertrophy as predictors of incident chronic kidney disease.

P2860

Q26740414-B67ACE26-EEDF-47CA-AA01-58EAB55FCB42 Q26863240-CF4B8869-1003-4F68-A72A-DCEEC8E5F7ED Q28184526-51E35FC4-42EF-4C1F-8210-E1D9DBFB94C3 Q28344781-EAB29F04-9FED-4DFD-98B6-7CBF8EC4E7DA Q28393763-F18D89F0-DF73-4D8A-B515-65372220AF0D Q28554193-52C7B566-97CC-4568-88A7-9116217FB9D0 Q29109541-CD838A61-4880-486A-AF70-F15133EA54AF Q30860042-F12F1C73-1B9B-4F97-B6B1-3E30468FD7CE Q30939425-743FB8D8-3CA0-4C37-82A4-D447A6D7DF2C Q33382616-E0199847-97F6-4C84-B008-AEE88BEC9A16 Q33404464-6DBD985D-407D-4A79-BF9B-7205B7722943 Q33578508-5C36AA64-53E8-4D97-BD40-A5E78AC3D742 Q33585696-8BFA1B0D-F475-46B5-9C26-DEA63079ACB0 Q33589563-C02F57E6-5183-4D2C-A579-FB0ED7F33BAB Q33602077-74F43284-BC09-4389-8B3A-AA0297B0911D Q33771352-F4D6F2E3-311A-48B5-B131-88C60A48F5DB Q33776176-B567F761-1A8B-43F1-9B03-E8B33275BA2C Q33776181-AB774B73-9618-42AE-97D4-1D8FE904DE91 Q33835707-BD43E708-2DD1-4735-B8CE-16708054E460 Q33948767-B5F3CE77-49D6-44CB-B1E0-369715A810BA Q34086005-140BEB90-9D06-45DC-9BCE-A2A9090AF9B2 Q34169794-93165EDE-6F49-4A70-8C7F-F7EA3C75C36C Q34237672-AEEB8AC5-0CA5-4D75-9A96-C72FFAF30CF1 Q34308238-88E602EC-DB1D-46F9-94C9-85BD2218579E Q34343449-1A06E64A-A115-4D6A-8239-024F8D49CE79 Q34559921-C16DB90C-1FD3-453C-AC29-A77CE96A5993 Q34572458-0144B619-43A8-4573-8AF5-20CB7171BFD1 Q34580123-20E30147-9445-41CA-A06D-21FB2BD9141E Q34595173-3C74EC30-B4C4-48BE-AB10-CE36311246BE Q34725449-AFC898C7-E074-4905-A0B7-4DE4313C4879 Q34793993-78694CA6-E908-45CC-B5A2-865EFC925EAD Q34795819-CE6B8938-8E2F-421A-8667-913FCB04090E Q34887952-6520B45D-EF8D-455F-9D6A-271A09AB5F61 Q34958618-1479B454-4D47-4722-80A0-89782C78E0A5 Q35046128-6DF299F3-D1A6-4D73-9809-C8C6BF15A31A Q35051131-5B8CD998-2461-48D7-87E2-0DAAC14B2FC6 Q35137813-E77165B7-7546-49D2-AC14-B573A9757E5F Q35203365-EDFE5FC7-8A9F-4FCD-A7CF-F4079B24F786 Q35204390-5F66B422-D966-4F85-8675-46D545B55F56 Q35211948-0BFB2348-B513-4600-B692-DD3A23B2B36C

P2860

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

http://www.wikidata.org/entity/Q51555214

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh

2000年學術文章

@zh-hant

name

Plasma lipids and risk of deve ...... sis risk in communities study.

@en

Plasma lipids and risk of deve ...... sis risk in communities study.

@nl

type

label

Plasma lipids and risk of deve ...... sis risk in communities study.

@en

Plasma lipids and risk of deve ...... sis risk in communities study.

@nl

prefLabel

Plasma lipids and risk of deve ...... sis risk in communities study.

@en

Plasma lipids and risk of deve ...... sis risk in communities study.

@nl

P1433

Q51555214-FCD7B1B4-8266-4E4A-9D89-4DC31991AB91

P1476

Q51555214-99579B54-4BEB-4D30-8BBF-1739071FEC45

P2093

Q51555214-225339E8-69F3-4098-8703-422A3410FE94

Q51555214-33876AA3-02C5-4524-9B04-B698CFBDAE3A

Q51555214-A428AD14-25A4-4C0A-BCB7-BA1DF4C7FB11

Q51555214-CB96EB33-A672-4FD7-9EC9-E17FD4EBC5BB

Q51555214-DFFB1C94-2EC9-4F4A-A6C1-6FFE84B2AE3C

P2888

Q51555214-18EF0272-4230-4B8D-BF31-82332D137C7B

P304

Q51555214-FAE7A5BD-A6D5-4031-AF83-B496F7E13184

P31

Q51555214-47A51E3B-357E-4BD1-86E3-3466991C8A78

P356

Q51555214-64B513A6-8B14-4E5B-8614-A37672A366E9

P407

Q51555214-A333A479-205C-4BED-80BC-02152C16AD3B

P433

Q51555214-5E567044-5F84-4476-903A-7E64D3E14C79

P478

Q51555214-8D257C96-3D8C-49C5-9691-7FC8B1E5ADD7

P577

Q51555214-816B2165-E26A-472C-B978-24AAFF0A5205

P5875

Q51555214-D2663EEF-8A0D-42C7-9400-37F87FBCFA68

P6179

Q51555214-82F321CF-B0D6-4518-AD4C-C22A089F3D3F

P698

Q51555214-806D5D9F-CF80-45E9-A07A-C141B1029925

P921

Q51555214-4A837976-E3E3-4865-A5C7-7BD8F10531A6

P356

J.1523-1755.2000.00165.X

P1433

Kidney International

P1476

Plasma lipids and risk of deve ...... sis risk in communities study.

@en

P2093

Coresh J

http://www.w3.org/2001/XMLSchema#string

Eckfeldt J

http://www.w3.org/2001/XMLSchema#string

Klag MJ

http://www.w3.org/2001/XMLSchema#string

Muntner P

http://www.w3.org/2001/XMLSchema#string

Smith JC

http://www.w3.org/2001/XMLSchema#string

P2888

j.1523-1755.2000.00165.x

P304

293-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1523-1755.2000.00165.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12431707

http://www.w3.org/2001/XMLSchema#string

P6179

1039605545

http://www.w3.org/2001/XMLSchema#string

P698

10886574

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis